Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) -- Fusemachines Inc. (NASDAQ: FUSE), a leading provider of enterprise AI products and services, today announced the rollout of its Agentic AI Assessment...
-
June 29, 2026 Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAPandUpdate on Serenta Progress Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”),...
-
WEST PALM BEACH, Florida, June 29, 2026 (GLOBE NEWSWIRE) -- Quantum Cyber N.V. (Nasdaq: QUCY) (“Quantum Cyber” or the “Company”), a Nasdaq-listed autonomous defense technology company assembling an...
-
Neve Yarak, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based...
-
ROCHESTER, NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) -- Syntec Optics Holdings, Inc. (NASDAQ: OPTX) (“Syntec Optics”), a premier provider of technology solutions for defense tech, space tech, and...
-
SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety,...
-
LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today...
-
NEW YORK, June 29, 2026 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in Happy City Holdings Ltd (Nasdaq: HCHL) for additional information requested...
-
SAN JOSE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused...
-
4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections4FRONT-2 over-enrolled (anticipated N>500), with final patient randomization expected in Q3 2026, reflecting...